Aurisco Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Aurisco Pharmaceutical Co Ltd working capital to net assets ratio. Aurisco Pharmaceutical Co Ltd (605116) has a Working Capital to Net Assets ratio of 64.5% as of June 2025. Working capital of CN¥1.57 Billion (current assets of CN¥2.01 Billion minus current liabilities of CN¥446.47 Million) is measured against net assets of CN¥2.43 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 605116 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Aurisco Pharmaceutical Co Ltd (2016–2024)
Working capital to net assets ratio of Aurisco Pharmaceutical Co Ltd from 2016 to 2024. This chart shows how Aurisco Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 64.5%, reflecting working capital of CN¥1.57 Billion against net assets of CN¥2.43 Billion CNY. See 605116 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Aurisco Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2016–2024)
Aurisco Pharmaceutical Co Ltd working capital to net assets ratio by year from 2016 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Aurisco Pharmaceutical Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 605116 current and non-current assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 65.0% | CN¥1.51 Billion | CN¥2.33 Billion | CN¥2.05 Billion | CN¥532.04 Million | ▲ +21.0 pp |
| 2023 | 44.0% | CN¥865.02 Million | CN¥1.97 Billion | CN¥1.37 Billion | CN¥501.02 Million | ▼ -1.5 pp |
| 2022 | 45.5% | CN¥766.19 Million | CN¥1.68 Billion | CN¥1.09 Billion | CN¥322.17 Million | ▼ -4.0 pp |
| 2021 | 49.5% | CN¥746.72 Million | CN¥1.51 Billion | CN¥939.80 Million | CN¥193.08 Million | ▼ -10.8 pp |
| 2020 | 60.4% | CN¥836.15 Million | CN¥1.39 Billion | CN¥977.76 Million | CN¥141.61 Million | ▲ +4.3 pp |
| 2019 | 56.1% | CN¥548.22 Million | CN¥977.28 Million | CN¥664.85 Million | CN¥116.64 Million | ▲ +2.2 pp |
| 2018 | 53.9% | CN¥424.19 Million | CN¥787.54 Million | CN¥553.76 Million | CN¥129.57 Million | ▼ -7.1 pp |
| 2017 | 61.0% | CN¥416.96 Million | CN¥683.95 Million | CN¥546.02 Million | CN¥129.07 Million | ▼ -5.4 pp |
| 2016 | 66.4% | CN¥391.69 Million | CN¥589.81 Million | CN¥581.14 Million | CN¥189.44 Million | — |